Demonstrates improved imaging of Aβ plaques in Alzheimer's patients, suggesting enhanced diagnostic capabilities.
Alzheimer's disease (AD) is neuropathologically defined by the deposition of β-amyloid (Aβ) plaques, a key diagnostic biomarker. However, current fluorescence probes targeting Aβ plaques are often limited by poor blood-brain barrier (BBB) penetration and short blood circulation half-lives, resulting in insufficient signal-to-noise ratios for in vivo imaging. To address this, we developed a rationally engineered near-infrared (NIR) fluorescent molecular probe library and implemented a tiered, closed-loop screening strategy for the discovery of probes, enabling high-fidelity in situ visualization of Aβ plaques. Through this integrated approach, we identified ADFP-2, which displays a high binding affinity for Aβ aggregates and exhibits a 34-fold fluorescence enhancement upon binding. Notably, ADFP-2 demonstrates optimal BBB penetrability and a prolonged circulation time, facilitating high-contrast in vivo imaging of Aβ deposits. This study not only provides a potent molecular tool for the early diagnosis of AD but also validates a systematic and efficient framework for probe discovery and optimization through engineered libraries and tiered screening.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: